Delcath Systems (DCTH) vs vVARDIS (VVVV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
vVARDIS is the larger company by market cap ($770.9 million vs $653.7 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DCTH | VVVV |
|---|---|---|
| Share price | $18.79 | $14.55 |
| Market cap | $653.67M | $770.91M |
| 1-day change | -2.34% | -3.00% |
| YTD return | +86.04% | — |
| 1-year return | +109.71% | — |
| 5-year return | +92.92% | — |
| P/E ratio (TTM) | 117.44 | — |
| Forward P/E | 68.95 | — |
| EPS (TTM) | $0.16 | $-0.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $85.23M | — |
| Revenue growth (YoY) | +129.08% | — |
| Net income (latest FY) | $2.70M | — |
| Gross margin | 86.16% | — |
| Operating margin | 0.77% | — |
| Net margin | 3.17% | — |
| 52-week high | $22.51 | $16.95 |
| 52-week low | $8.49 | $14.00 |
| Distance from 52-week high | -16.53% | -14.16% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +52.21% | — |
| Average volume | 497.48K | 963.08K |
| Shares outstanding | 34.79M | 38.59M |
| Employees | 156 | 153 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Delcath Systems
DCTH stock →Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Health Care · Medical/Dental Instruments · 156 employees
About vVARDIS
VVVV stock →vVARDIS Holding AG, a dental medtech company, develops and provides non-invasive cavity treatment products in Switzerland and the United States. The company offers the Curodont platform, including Curodont Repair, a biomimetic system to arrest and reverse early caries through enamel regeneration; Curodont Protect, a remineralising tooth gel containing the biomimetic Oligo-Peptide 103 technology; and Enamel Serum, enriched with peptides and hydroxyapatite, which delivers calcium and phosphate ions to care for the enamel.
Health Care · Medical/Dental Instruments · 153 employees
DCTH vs VVVV FAQ
Which is bigger, Delcath Systems or vVARDIS?
vVARDIS (VVVV) is larger, with a market capitalization of $770.91M compared with $653.67M for Delcath Systems (DCTH).
Are Delcath Systems and vVARDIS in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.